It is up to a federal judge to decide the fate of a patent lawsuit against Myriad Genetics Inc., which has patented genes that are linked to an increased risk of breast and ovarian cancers. According to the lawsuit, Myriad Genetic refuses to allow anyone else to broadly research the genes, which forces anyone who fears they may be at risk of breast or ovarian cancer to deal with Myriad alone. The test to identify if the genes have specific mutations that could increase the risk for cancer costs as much as $3,000. The lawsuit also contends that the development of treatments are being restricted